CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Elan Pharma International Limited v. Abraxis Bioscience Inc.

1:06-cv-00438

Overview

Case Number 1:06-cv-00438
Filing Date 2006-07-19
Status Terminated
Termination Date 2011-03-02
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 28:1338 Patent Infringement
Jury Demand Both

Parties

Counter Claimant

Abraxis Bioscience Inc. Operating Company

Represented By

9 Attorneys Listed

Counter Defendant

Elan Pharma International Limited NPE (University / Research)

Represented By

6 Attorneys Listed

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 17 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (17): πŸ‡¨πŸ‡¦ Canada CN πŸ‡©πŸ‡ͺ Germany πŸ‡ͺπŸ‡Ί Europe πŸ‡―πŸ‡΅ Japan KR πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US5399363
Surface modified anticancer nanoparticles
Filed: 1992-07-01
Issued: 1995-03-21
Expired (Term Ended)
Expires: 2012-07-01
US5834025
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
Filed: 1996-08-14
Issued: 1998-11-10
Expired (Term Ended)
Expires: 2016-08-14

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

135

Dispositive

11

Granted

4

Denied

5

Pending / Review

125

Motions by Category

Procedural / Extension Motion 22 Motion to Strike / Sanctions 15 Claim Construction / Markman Filing 27 Motion to Compel Discovery 60 Motion to Dismiss 6 Motion for Summary Judgment (Rule 56) 5

Key Dispositive Motions & Rulings

Motion for Summary Judgment (Rule 56) Pending / Under Review
REDACTED VERSION of 453 Letter, to The Honorable Gregory M. Sleet from Karen E. Keller regarding Defendant's reply letter in support of its letter requesting pe...
Entry #458 • 2008-01-16 Document →
Motion for Summary Judgment (Rule 56) Pending / Under Review
Letter to The Honorable Gregory M. Sleet from Karen E. Keller regarding Defendant's reply letter in support of its letter requesting permission to file motion f...
Entry #453 • 2008-01-14 Document →
Motion for Summary Judgment (Rule 56) Pending
REDACTED VERSION of 446 Letter to The Honorable Gregory M. Sleet regarding Defendant's request for permission to file motion for summary judgment by Abraxis Bio...
Entry #449 • 2008-01-07 Document →
Motion for Summary Judgment (Rule 56) Pending / Under Review
REDACTED VERSION of 446 Letter to The Honorable Gregory M. Sleet regarding Defendant's request for permission to file motion for summary judgment by Abraxis Bio...
Entry #449 • 2008-01-07 Document →
Motion for Summary Judgment (Rule 56) Pending / Under Review
Letter to The Honorable Gregory M. Sleet from Karen E. Keller regarding Defendant's request for permission to file motion for summary judgment (FILED UNDER SEAL...
Entry #446 • 2008-01-02 Document →
Motion to Dismiss Granted
ORDER granting 363 Letter motion to dismiss newly added infringement contentions. Signed by Judge Gregory M. Sleet on 12/6/2007. (asw) (Entered: 12/06/2007)
Entry #437 • 2007-12-06 Document →

Docket Entries

(702 total)
Pleading / Complaint

COMPLAINT filed with Jury Demand against Abraxis Bioscience Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 350, receipt number 144083.) - filed by Elan Pharmaceutical International Limited. (Attachments: # 1 Exhibit A# 2 Exhibit B# 3 Civil Cover Sheet)(els, ) Additional attachment(s) added on 7/20/2006 Acknowledgement of Consent Form (els, ). (Entered: 07/20/2006)

Entry #1 • 2006-07-19
1

Notice of Availability of a U.S. Magistrate Judge to Exercise Jurisdiction (els, ) (Entered: 07/20/2006)

Entry #2 • 2006-07-19
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,399,363; 5,834,025; (els, ) (Entered: 07/20/2006)

Entry #3 • 2006-07-19
1
Pleading / Complaint

Return of Service Executed by Elan Pharmaceutical International Limited. Abraxis Bioscience Inc. served on 7/19/2006, answer due 8/8/2006. (Horwitz, Richard) (Entered: 07/21/2006)

Entry #4 • 2006-07-21
1

NOTICE OF SUBSTITUTION OF COUNSEL re Elan Pharmaceutical International Limited: Entry of appearance of attorney Steven J. Balick. Attorney Richard L. Horwitz terminated. (Balick, Steven) (Entered: 07/27/2006)

Entry #5 • 2006-07-27
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc